Huadao Bio

华道生物

Huadao Bio

Biotech/Healthcare

Founded in September 2017, Huadao Biotech focuses on developing autologous CAR-T cell therapies for hematologic malignancies and solid tumors, as well as independent innovation across the full cell immunotherapy value chain. In October 2019, its first cell therapy candidate, CD19 CAR-T cells…

Latest round: Series D Extension+ (2025)

Source: ChinaBulls — chinabulls.com

Last updated 2025-10-01